P140 a dudToday 16:45
Seems they knew when they published results as no mention of a possible deal this year
P140 technology platform
· Continued progress with the Company's P140 autoimmune technology platform, which remains ImmuPharma's lead asset and core value driver
· As highlighted in the patent application submission in September 2025, P140 is being developed alongside the Type M companion diagnostic platform, designed to identify "super-responder" patients and enable a precision medicine approach in autoimmune diseases
· The recent P140 scientific update in April 2026, further strengthened the program's foundations, highlighting the first Combined Search and Examination Report for the UK patent application, supported by new study data
· A scientific manuscript is now in preparation for submission to a peer-reviewed journal
· These developments enhance the credibility and long-term commercial potential of P140